Score for the Survival Probability in Metastasis Breast Cancer: A Nomogram-Based Risk Assessment Model
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Survival of metastatic breast cancer (MBC) patient remains unknown and varies greatly from person to person. Thus, we aimed to construct a nomogram to quantify the survival probability of patients with MBC. Materials and Methods We had included 793 MBC patients and calculated trends of case fatality rate by Kaplan- Meier method and joinpoint regression. Six hundred thirty-four patients with MBC between January 2004 and July 2011 and 159 patients with MBC between August 2011 and July 2013 were assigned to training cohort and internal validation cohort, respectively. We constructed the nomogram based on the results of univariable and multivariable Cox regression analyses in the training cohort and validated the nomogram in the validation cohort. Concordance index and calibration curves were used to assess the effectiveness of nomogram. Results Case fatality rate of MBC was increasing (annual percentage change [APC], 21.6; 95% confidence interval [CI], 1.0 to 46.3; p < 0.05) in the first 18 months and then decreased (APC, 4.5; 95% CI, 8.2 to 0.7; p < 0.05). Metastasis-free interval, age, metastasis location, and hormone receptor status were independent prognostic factors and were included in the nomogram, which had a concordance index of 0.69 in the training cohort and 0.67 in the validation cohort. Calibration curves indicated good consistency between the two cohorts at 1 and 3 years. Conclusion In conclusion, the fatality risk of MBC was increasing and reached the summit between 13th and 18th month after the detection of MBC. We have developed and validated a nomogram to predict the 1- and 3-year survival probability in MBC.
Abstract
Purpose Survival of metastatic breast cancer (MBC) patient remains unknown and varies greatly from person to person. Thus, we aimed to construct a nomogram to quantify the survival probability of patients with MBC. Materials and Methods We had included 793 MBC patients and calculated trends of case fatality rate by Kaplan- Meier method and joinpoint regression. Six hundred thirty-four patients with MBC between January 2004 and July 2011 and 159 patients with MBC between August 2011 and July 2013 were assigned to training cohort and internal validation cohort, respectively. We constructed the nomogram based on the results of univariable and multivariable Cox regression analyses in the training cohort and validated the nomogram in the validation cohort. Concordance index and calibration curves were used to assess the effectiveness of nomogram. Results Case fatality rate of MBC was increasing (annual percentage change [APC], 21.6; 95% confidence interval [CI], 1.0 to 46.3; p < 0.05) in the first 18 months and then decreased (APC, 4.5; 95% CI, 8.2 to 0.7; p < 0.05). Metastasis-free interval, age, metastasis location, and hormone receptor status were independent prognostic factors and were included in the nomogram, which had a concordance index of 0.69 in the training cohort and 0.67 in the validation cohort. Calibration curves indicated good consistency between the two cohorts at 1 and 3 years. Conclusion In conclusion, the fatality risk of MBC was increasing and reached the summit between 13th and 18th month after the detection of MBC. We have developed and validated a nomogram to predict the 1- and 3-year survival probability in MBC.
참고문헌 (30)
- DeSantis C, "Breast cancer statistics, 2013", CA Cancer J Clin, 64, pp.52~62 (2014)
- Miao H, "Predicting survival of de novo metastatic breast cancer in Asian women: systematic review and validation study", PLoS One, 9, pp.e93755~ (2014)
- Cardoso F, "3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)", Ann Oncol, 28, pp.16~33 (2017)
- Turner NC, "Advances in the treatment of advanced oestrogen-receptor-positive breast cancer", Lancet, 389, pp.2403~2414 (2017)
- Harbeck N, "Breast cancer", Lancet, 389, pp.1134~1150 (2017)
- Amin MB, "The eighth edition AJCC cancer staging manual: continuing to build a bridge from a populationbased to a more "personalized" approach to cancer staging", CA Cancer J Clin, 67, pp.93~99 (2017)
- "MammaPrint reduces breast cancer overtreatment", Cancer Discov, 6, pp.OF4~ (2016)
- Kennecke H, "Metastatic behavior of breast cancer subtypes", J Clin Oncol, 28, pp.3271~3277 (2010)
- Lin C, "CGI-99 promotes breast cancer metastasis via autocrine interleukin-6 signaling", Oncogene, 36, pp.3695~3705 (2017)
- Lee ES, "Identifying the potential long-term survivors among breast cancer patients with distant metastasis", Ann Oncol, 27, pp.828~833 (2016)
- den Brok WD, "Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed", Breast Cancer Res Treat, 161, pp.549~556 (2017)
- Eng LG, "Ten-year survival in women with primary stage IV breast cancer", Breast Cancer Res Treat, 160, pp.145~152 (2016)
- Lobbezoo DJ, "Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?", Br J Cancer, 112, pp.1445~1451 (2015)
- Wang H, "The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: a SEER based study", Oncotarget, 8, pp.26368~26379 (2017)
- Rapiti E, "Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis", J Clin Oncol, 24, pp.2743~2749 (2006)
- Gong Y, "Impact of molecular subtypes on metastatic breast cancer patients: a SEER populationbased study", Sci Rep, 7, pp.45411~ (2017)
- Robertson JF, "Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, doubleblind, phase 3 trial", Lancet, 388, pp.2997~3005 (2016)
- Denkert C, "Molecular alterations in triple-negative breast cancer: the road to new treatment strategies", Lancet, 389, pp.2430~2442 (2017)
- Graesslin O, "Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer", J Clin Oncol, 28, pp.2032~2037 (2010)
- 임유진, "A Novel Prognostic Nomogram for Predicting Risks of Distant Failure in Patients with Invasive Breast Cancer Following Postoperative Adjuvant Radiotherapy", Cancer Research and Treatment, 50(4), pp.1140~1148 (2018), 대한암학회
- 김민균, "Nomogram for Predicting Breast Conservation after Neoadjuvant Chemotherapy", Cancer Research and Treatment, 47(2), pp.197~207 (2015), 대한암학회[DOI]
- Dawood S, "Survival differences among women with de novo stage IV and relapsed breast cancer", Ann Oncol, 21, pp.2169~2174 (2010)
- Thomas A, "Initial surgery and survival in stage IV breast cancer in the United States, 1988-2011", JAMA Surg, 151, pp.424~431 (2016)
- [URL]
- Di Meglio A, "Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis", Breast Cancer Res Treat, 157, pp.587~596 (2016)
- Di Lascio S, "Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?", Breast Care (Basel), 9, pp.7~14 (2014)
- 박수진, "Risk Factors Associated with Distant Metastasis and Survival Outcomes in Breast Cancer Patients with Locoregional Recurrence", Journal of Breast Cancer, 18(2), pp.160~166 (2015), 한국유방암학회
- Iasonos A, "How to build and interpret a nomogram for cancer prognosis", J Clin Oncol, 26, pp.1364~1370 (2008)
- Hart CD, "Challenges in the management of advanced, ER-positive, HER2-negative breast cancer", Nat Rev Clin Oncol, 12, pp.541~552 (2015)
- Wang X, "Acylglycerol kinase promotes cell proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor", Mol Cancer, 13, pp.106~ (2014)